Navigation Links
PDL BioPharma Completes October 1 Special Dividend Payment
Date:10/1/2009

INCLINE VILLAGE, Nev., Oct. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has paid the October 1, 2009 special dividend payment of $0.50 per share to all stockholders owning shares of PDL as of September 17, 2009.

As previously announced, the conversion rate for the Company's 2.00% Convertible Senior Notes due February 15, 2012 was adjusted to 94.447 shares of common stock per $1,000 principal amount, as a result of the dividend payment. The conversion rate for the 2.75% Convertible Subordinated Notes due August 16, 2023 was also adjusted to 131.0339 shares of common stock per $1,000 principal amount.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
2. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
3. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
4. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
5. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
6. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
7. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
8. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
9. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
10. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...s., Nov. 25 Hologic, Inc...ding developer, manufacturer and supplier of premi...al products dedicated to serving the healthcare ne...adiological Society of North America (RSNA) at McC...ber 3, 2009 to highlight our new SecurView(®)...
(Date:11/25/2009)...FA, Switzerland, Nov. 25 From Nov...nnovative hearing solutions, presented the second ... focusing on the special needs of the older popula...rts in aging and audiology from around the world a... older people with hearing loss for an opportunity...
(Date:11/25/2009)...CH, Fla., Nov. 25 For ma...especially the 27 million living with untreated h...py, says audiologist Cindy Beyer. ,, Dr. Beyer,...ne of America,s largest hearing care and hearing ...loss to stress, frustration, and social isolation,...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3GfK Asia Expands into Korea Optics Industry Partnership Network 49569 1GfK Asia Expands into Korea Optics Industry Partnership Network 49569 2GfK Asia Expands into Korea Optics Industry Partnership Network 49569 3Premium Latex Condom Donation by IBI Synergy Inc Are You Looking For a Few Good Latex Condoms 3F 49567 1Premium Latex Condom Donation by IBI Synergy Inc Are You Looking For a Few Good Latex Condoms 3F 49567 2Premium Latex Condom Donation by IBI Synergy Inc Are You Looking For a Few Good Latex Condoms 3F 49567 3US Brachytherapy Market to Reach 241 6 Billion by 2015 According to New Report by Global Industry Analysts Inc 49562 1US Brachytherapy Market to Reach 241 6 Billion by 2015 According to New Report by Global Industry Analysts Inc 49562 2US Brachytherapy Market to Reach 241 6 Billion by 2015 According to New Report by Global Industry Analysts Inc 49562 3
...t Ever Phase III Clinical Trial in,Lung Cancer Tre...rstCall/ --,GlaxoSmithKline today announced final ...ial of its investigational MAGE-A3,Antigen-Specifi...ive patients with stage IB or II Non-Small Cell Lu...e 2007 American Society of,Clinical Oncology (ASCO...
...RE)--Jun 5, 2007 - Synta,Pharmaceuticals Corp., (N...n discovering, developing, and commercializing sma...ns, today announced,encouraging results from the a... in the Company,s double-blind, randomized, contro...static melanoma for its,lead compound, STA-4783., ...
Other Medicine Technology:Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 2Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 3Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 4Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 6Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 2Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 3Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 4Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 5Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 6Synta Presents Results for STA-4783 in Metastatic Melanoma Showing,Improvement in Overall Survival 7
(Date:11/28/2009)..., recognize signs of depression , , SATU..., the holiday season can trigger melancholy as the...h issues or worry about money problems, according ...vercome the seasonal blues, the AGS Foundation for...Get out and socialize or invite family and friends...
(Date:11/27/2009)...wire/ - Uploadable USB pedometers may be new, but ...ombination of advanced accelerometer functionality... concern over the accuracy of self-reported data. ...mproved participation in a fitness program. ,, ...ss suppliers to integrate this technology. "Our he...
(Date:11/27/2009)...-USNewswire/ -- Considered a highly risky and cont...id organ transplantation is now a life-saving main...nd women who gathered at the Winspear Opera House ...edical centers around the world to celebrate the 2...itute (BRTI), one of the pioneers of solid organ t...
(Date:11/27/2009)...RNewswire-USNewswire/ -- Preventing disease is the...y every year, new vaccines are being added to assi...t immunity for the same period of time? And, if no...eep immunity strong? ,, In this month,s issue...y of Pediatrics, Michael Pichichero MD, Director o...
(Date:11/27/2009)... 27 Shamir Optical Indus...provider of innovative products and technology to ...ts board of directors had declared a dividend dist...(approximately NIS 37.62 million based on the Nove... approximately US$ 0.609 (approximately NIS 2.3 ba...
Breaking Medicine News(10 mins):Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3
...nto how that happens may lead to ways around it, r...lthDay News) -- Temozolomide, a standard treatment... surviving cancer cells, making tumor recurrence m...mors called gliomas that have stem cell-like quali...
...rds 172% Year over Year Revenue Growth and First F...Lead Insulet,s International Expansion , , Brian ... Insulet Corporation (Nasdaq: PODD ), the leade...ull year ended December 31, 2008. , , Fourth ...
...ch 5 Trubion Pharmaceuticals Inc. (Nasdaq: TRBN... results for the fourth quarter and year ended Dec... 2009. The company,s earnings conference call will... http://investors.trubion.com . , , Fourth-Quart...
... The editors of the Harvard Health Le...torial board, propose 12 ways you can help curb he...urself--some money , Bost...reover, even people with good health insurance are...
...vides Relief on Premiums, Re-enrollment Opportunit...missioner Joel Ario today advised Pennsylvanians w...health insurance to know that that the federal sti...Pennsylvanians know that additional help in paying...
...March 5 The following is a statement of Matthew L...: , , (Logo: http://www.newscom.com/cgi-bin/prnh...allone (NJ-6) for his strong leadership in advanci...d crack down on tobacco marketing and sales to kid...
Other Medicine News:Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 2Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 4Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 5Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 6Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 7Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 8Health News:Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 3Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2Health News:Rep. Frank Pallone is Leader on Bill to Protect Kids from Tobacco 2
Reference Lab Interface (RLI)©
PM-9000 Express Patient Monitor
...M-labeled probe that is designed to detect Flu A a...addition, this ASR contains primers and a Texas Re...ntrol. This ASR requires an instrument that can de...ch as the Cepheid SmartCycler System. The Cepheid ...
...beled probe that is designed to detect Respiratory...ains primers and a Texas Red-labeled probe for a,...ires an instrument that can detect FAM and Texas R...ystem. The Cepheid Analyte Specific Reagent* (ASR)...
Medicine Products: